Vanguard Capital Management
SPRB icon

Vanguard Capital Management’s Spruce Biosciences SPRB Stock Holding History

Vanguard Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.8M Hold
119,331
– – ﹤0.01% 3023
2026
Q2 		$6.44M Buy
119,331
+100,994
+551% +$5.65M ﹤0.01% 3025
2026
Q1 		$1.2M Buy
+18,337
New +$1.27M ﹤0.01% 3507

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Quinn Opportunity Partners
Quinn Opportunity Partners Charlottesville, Virginia $1.85B AUM 1.27% 1-Year Est. Return
DMKJ
David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Persistent Asset Partners
Persistent Asset Partners Hong Kong $362M AUM 191.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management's SPRB Position: Q3 2026 in Review

Vanguard Capital Management held its Spruce Biosciences (SPRB) position steady in Q3 2026 at 119,331 shares worth $5.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Vanguard Capital Management first reported a position in SPRB in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.44M in Q2 2026. 40 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.

  • Vanguard Capital Management held 119,331 shares of Spruce Biosciences worth $5.8M as of Q3 2026.
  • Vanguard Capital Management left its Spruce Biosciences share count unchanged in Q3 2026.
  • Spruce Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3023 holding.
  • Vanguard Capital Management first reported a position in Spruce Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Spruce Biosciences position peaked at $6.44M in Q2 2026.
  • 40 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.